New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
07:12 EDTVRX, BMY, ABC, BDX, BIIB, TMO, MYLGoldman to hold a conference
Healthcare CEOs Unscripted Conference is being held in Boston on January 7.
News For MYL;BDX;BMY;TMO;ABC;VRX;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 17, 2015
08:56 EDTBMYBristol-Myers says Phase III Opdivo study met endpoint, trial stopped early
Subscribe for More Information
08:00 EDTMYLTeva patent loss should move management to acquire Mylan, says Cowen
Subscribe for More Information
05:53 EDTMYLStocks with implied volatility movement; XLNX MYL
Subscribe for More Information
April 16, 2015
15:40 EDTMYLGeneric Copaxone approval a bit early but expected, says BMO Capital
BMO Capital believes FDA approval for Sandoz (NVS) and Momenta's (MNTA) generic 20mg Copaxone came slightly earlier than the market expected, but the firm added that the generic threat has been well expected. The firm added that it appears Mylanís (MYL) generic Copaxone hasn't been approved yet, leaving a "legitimate question" about why the FDA approved one generic and not the other. BMO thinks Teva's rate of conversion to the 40mg dose will help retain patients on the Copaxone franchise and it keeps an Outperform rating on Teva shares.
12:16 EDTBMYEli Lilly and Bristol-Myers restructure Erbitux collaboration in N. America
Subscribe for More Information
08:59 EDTBMYGene therapy companies could benefit from increased attention, says Roth Capital
Subscribe for More Information
07:05 EDTABCNovaBay signs distribution agremeent with AmerisourceBergen
Subscribe for More Information
April 15, 2015
12:01 EDTBDXBecton Dickinson price target raised to $167 from $160 at Piper Jaffray
Subscribe for More Information
09:08 EDTBMYOn The Fly: Pre-market Movers
Subscribe for More Information
09:02 EDTMYLRBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
07:41 EDTTMO, BMYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
07:14 EDTBIIBBiogen volatility flat into new drug data
Biogen overall option implied volatility of 35 compares to its 26-week average of 34 according to Track Data, suggesting non-directional into results as shares rally in the preopen on Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis clinical data.
07:03 EDTBMYLexicon and Bristol-Myers select development candidate for neuropathic pain
Subscribe for More Information
April 14, 2015
18:30 EDTBIIBOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTBIIBBiogen presents new Anti-LINGO-1 Phase 2 AON data
Subscribe for More Information
11:25 EDTBIIBPTAB declares interference between Forward Pharma and Biogen regarding treatment
Subscribe for More Information
10:16 EDTTMOHigh option volume stocks
High option volume stocks: NSAM ALU CJES BIG CMRX ERIC NTAP TMO KN CIG
April 13, 2015
15:12 EDTMYLMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.
07:56 EDTMYLMylan, Teva, Perrigo price targets raised at JPMorgan
Subscribe for More Information
06:49 EDTMYLMylan notifies Perrigo of HSR filing regarding proposed acquisition
Mylan N.V. (MYL) announced that it has provided Perrigo (PRGO) with notice of its filing of the premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use